Vaxart, Inc. (NASDAQ:VXRT – Get Rating) CFO Fuad Ahmad acquired 5,000 shares of the stock in a transaction dated Wednesday, June 22nd. The stock was acquired at an average price of $3.22 per share, for a total transaction of $16,100.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $16,100. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of VXRT stock traded up $0.26 during trading hours on Thursday, hitting $3.69. The stock had a trading volume of 2,771,725 shares, compared to its average volume of 2,662,238. Vaxart, Inc. has a one year low of $2.49 and a one year high of $10.33. The stock’s 50-day moving average price is $3.54 and its two-hundred day moving average price is $4.74. The stock has a market capitalization of $466.44 million, a price-to-earnings ratio of -5.77 and a beta of 0.67.
Vaxart (NASDAQ:VXRT – Get Rating) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Vaxart had a negative return on equity of 41.95% and a negative net margin of 16,892.57%. The firm had revenue of $0.09 million during the quarter. As a group, analysts forecast that Vaxart, Inc. will post -0.75 EPS for the current year.
Separately, B. Riley lowered their price objective on Vaxart from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Thursday, May 19th.
Vaxart Company Profile (Get Rating)
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.